NCT01970501
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
See it on ClinicalTrials.gov ↗267 people
18%
82%
48 womenmiddle line = equal numbers219 men
- Phase
- PHASE2
- Paid for by
- ARCA Biopharma, Inc.
- Finished
- 2017-12-28
- Health conditions
- Current or Recent History of Atrial Fibrillation
- Who could join
- Anyone
- Ages
- 18 Years – 85 Years
- Average age
- mean 65 years
- Age 65+
- 59.2%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 96.3% · Black / African American 1.9% · Asian 0.7% · American Indian / Alaska Native 0.4% · Native Hawaiian / Pacific Islander 0.4% · Not reported 0.4% · More than one race 0%
Women left out
No rules that kept women out were found.
Study titles and rules are shown in their original English.